Journal article · 2021 · Open access

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul Trafford Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona M. Burns, David Chadwick, Rebecca Clark, Catherine Cosgrove, James Benjamin Galloway, Anna L. Goodman, Amardeep Heer and 33 more

New England Journal of Medicine, 385(13), 1172–1183 · Published 30 June 2021 · DOI 10.1056/nejmoa2107659

Open PDFView at the publisherCite this paper

In brief

“Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine” is a 2021 journal article by Paul Trafford Heath and 44 co-authors, published in New England Journal of Medicine. OpenAlex counts 1,173 citations as of 20 November 2026. It is open access: the full text is free to read at medRxiv.

Citations
1,173
Most cited in
2022 (396)
Field-weighted impact
76.73
References
14
Authors
45

Abstract

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population. METHODS: In this phase 3, randomized, observer-blinded, placebo-controlled trial conducted at 33 sites in the United Kingdom, we assigned adults between the ages of 18 and 84 years in a 1:1 ratio to receive two intramuscular 5-μg doses of NVX-CoV2373 or placebo administered 21 days apart. The primary efficacy end point was virologically confirmed mild, moderate, or severe SARS-CoV-2 infection with an onset at least 7 days after the second injection in participants who were serologically negative at baseline. RESULTS: A total of 15,187 participants underwent randomization, and 14,039 were included in the per-protocol efficacy population. Of the participants, 27.9% were 65 years of age or older, and 44.6% had coexisting illnesses. Infections were reported in 10 participants in the vaccine group and in 96 in the placebo group, with a symptom onset of at least 7 days after the second injection, for a vaccine efficacy of 89.7% (95% confidence interval [CI], 80.2 to 94.6). No hospitalizations or deaths were reported among the 10 cases in the vaccine group. Five cases of severe infection were reported, all of which were in the placebo group. A post hoc analysis showed an efficacy of 86.3% (95% CI, 71.3 to 93.5) against the B.1.1.7 (or alpha) variant and 96.4% (95% CI, 73.8 to 99.5) against non-B.1.1.7 variants. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups. CONCLUSIONS: A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16.).

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C., Galloway, J. B., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jamal, A., Jeanes, C., Kalra, P. A., Kyriakidou, C., McAuley, D. F., . . . Toback, S. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine, 385(13), 1172–1183. https://doi.org/10.1056/nejmoa2107659

MLA 9

Heath, Paul Trafford, et al. “Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.” New England Journal of Medicine, vol. 385, no. 13, 2021, pp. 1172–1183. https://doi.org/10.1056/nejmoa2107659.

Chicago

Heath, Paul Trafford, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona M. Burns, David Chadwick, et al. 2021. “Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.” New England Journal of Medicine 385 (13): 1172–1183. https://doi.org/10.1056/nejmoa2107659.

Harvard

Heath, P. T. et al. (2021) ‘Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine’, New England Journal of Medicine, 385(13), pp. 1172–1183. doi:10.1056/nejmoa2107659.

IEEE

P. T. Heath et al., “Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,” New England Journal of Medicine, vol. 385, no. 13, pp. 1172–1183, 2021, doi: 10.1056/nejmoa2107659.

BibTeX

@article{heath2021safety,
  title     = {{Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine}},
  author    = {Heath, Paul Trafford and Galiza, Eva P. and Baxter, David Neil and Boffito, Marta and Browne, Duncan and Burns, Fiona M. and Chadwick, David and Clark, Rebecca and Cosgrove, Catherine and Galloway, James Benjamin and Goodman, Anna L. and Heer, Amardeep and Higham, Andrew and Iyengar, Shalini and Jamal, Arham and Jeanes, Christopher and Kalra, Philip A. and Kyriakidou, Christina and McAuley, Daniel Francis and Meyrick, Agnieszka and Minassian, Angela M. and Minton, Jane and Moore, Patrick and Munsoor, Imrozia and Nicholls, Helen and Osanlou, Orod and Packham, Jonathan and Pretswell, Carol H. and Ramos, Alberto San Francisco and Saralaya, Dinesh and others},
  journal   = {New England Journal of Medicine},
  year      = {2021},
  volume    = {385},
  number    = {13},
  pages     = {1172--1183},
  doi       = {10.1056/nejmoa2107659},
  url       = {https://doi.org/10.1056/nejmoa2107659}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201311
2021136136
2022396396
2023262262
2024176176
2025129129
20267373

Its field-weighted citation impact is 76.73: it has been cited 76.73 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • NVX-CoV2373
  • Novavax
  • COVID-19 vaccines
  • SARS-CoV-2
  • Matrix-M adjuvant
  • spike protein
  • vaccine efficacy
  • vaccine safety

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C., Galloway, J. B., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jamal, A., Jeanes, C., Kalra, P. A., Kyriakidou, C., McAuley, D. F., . . . Toback, S. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine, 385(13), 1172–1183. https://doi.org/10.1056/nejmoa2107659

How many times has this paper been cited?

1,173 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at medRxiv: sign in and open the PDF from this page.

Who wrote this paper?

Paul Trafford Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona M. Burns, David Chadwick, Rebecca Clark, Catherine Cosgrove, James Benjamin Galloway, Anna L. Goodman, Amardeep Heer and 33 more.

What is the DOI of this paper?

10.1056/nejmoa2107659, permanently at https://doi.org/10.1056/nejmoa2107659. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.